Global Alogliptin Market Size, Share and Trends Analysis Report, By Product Type (6.25 mg Tablet, 25 mg Tablet, 12.5 mg Tablet, 15 mg Tablet, and Others), By Application (Diabetes, Hypercholesterolemia, Obesity, and Others), Forecast (2022-2028)

The global alogliptin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Alogliptin is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus, however, it is not used to treat type 1 diabetes. The major factor expected to drive the market is the rising incidences of diabetes. Diabetes is a chronic illness associated with microvascular complications such as nephropathy (kidney disease), retinopathy (eye damage), and neuropathy (nervous system damage).

Alogliptin is used to control high blood sugar in people with type 2 diabetes which supports prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It works by increasing levels of natural substances called incretins. Incretins supports to control blood sugar by increasing insulin release, especially after a meal also it decreases the amount of sugar liver makes. Additionally, the study performed till now on alogliptin has not demonstrated geriatric-specific problems that would limit the usefulness of alogliptin in the elderly and also that there is no infant risk when using this medication during breastfeeding.

Some major players in the market include Takeda Pharmaceutical Co., Ltd., AbbVie Inc., and Hikma Pharmaceuticals plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, STADA declared that it will launch a drug for the complex treatment of type 2 diabetes on the Russian market. This comprises a combination of two active substances, such as pioglitazone and alogliptin. The combination of both these active substances simultaneously affects the prime pathogenetic mechanisms of the development and progression of type 2 diabetes. This, in turn, ensures effective and long-term control of blood sugar levels.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Product Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Takeda Pharmaceutical Co., Ltd., AbbVie Inc., and Hikma Pharmaceuticals plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Alogliptin Market Report by Segment

By Product Type

• 25 Mg Tablet
• 25 Mg Tablet
• 5 Mg Tablet
• 15 Mg Tablet
• Others

By Application

• Diabetes
• Hypercholesterolemia
• Obesity
• Others

Global Alogliptin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa